Clinical Trials Logo

Cicatrizing Conjunctivitis clinical trials

View clinical trials related to Cicatrizing Conjunctivitis.

Filter by:
  • None
  • Page 1

NCT ID: NCT05263505 Terminated - Clinical trials for Mucous Membrane Pemphigoid

Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid

Start date: February 21, 2022
Phase: Phase 2
Study type: Interventional

Ocular mucous membrane pemphigoid (MMP) is an autoimmune, scarring conjunctivitis that can lead to vision loss and permanent disability. It is a rare disorder with an estimated incidence of 1 in 60,000. There are currently no FDA-approved medications for the treatment of mucous membrane pemphigoid, highlighting a clear unmet need. At present, moderate to severe disease requires off-label use of potent immunosuppressive agents, such as oral anti-proliferatives (methotrexate, azathioprine, and mycophenolate), rituximab (RTX) or cyclophosphamide (CyC). Recently, Janus kinase (JAK) inhibition with baricitinib or tofacitinib been reported to be successful in one case of ocular MMP. This is a randomized, single-masked, two-arm study of baricitinib vs anti-proliferatives for ocular MMP.

NCT ID: NCT03839069 Recruiting - Clinical trials for Chronic Graft Versus Host Disease

Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis

Start date: September 2016
Phase: N/A
Study type: Interventional

This is a prospective study that aimed to observe the therapeutic effects of minor salivary gland transplantation for cicatrizing conjunctivitis patients.